A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2002
11/28/2002	WO2002094185A2 Conjugates and compositions for cellular delivery
11/28/2002	WO2002094180A2 Pharmaceutically active isoindoline derivatives
11/28/2002	WO2002094176A2 Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
11/28/2002	WO2002094019A1 Highly purified antiendotoxin compound
11/28/2002	WO2002085897A8 Heterocyclic compounds for aging-related and diabetic vascular complications
11/28/2002	WO2002083712A8 Transporters and ion channels
11/28/2002	WO2002080887A3 Timed pulse release composition
11/28/2002	WO2002080648A3 Mucosal boosting following parenteral priming
11/28/2002	WO2002079408A3 Short bioactive peptides and methods for their use
11/28/2002	WO2002073235A3 Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
11/28/2002	WO2002072631A8 Mhc molecule constructs and their usesfor diagnosis and therapy
11/28/2002	WO2002072008A9 Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
11/28/2002	WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002	WO2002070532A3 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
11/28/2002	WO2002066636A3 T cell receptor variants expressed in mesenchymal cells and uses thereof
11/28/2002	WO2002062979A3 Enzyme
11/28/2002	WO2002062777A3 Amino ceramide-like compounds and therapeutic methods of use
11/28/2002	WO2002057741A3 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
11/28/2002	WO2002057273A9 Serine protease inhibitors comprising a hydrogen-bond acceptor
11/28/2002	WO2002057223A3 Compounds azepane, preparation method therefor and pharmaceutical compositions containing said compounds
11/28/2002	WO2002050304A3 Oncolytic virus
11/28/2002	WO2002047711A3 Modulators of activity of g-protein-coupled receptor kinases
11/28/2002	WO2002044153A8 4-6-diphenyl pyridine derivatives as antiinflammatory agents
11/28/2002	WO2002036733A3 Cd36 as a heat shock protein receptor and uses thereof
11/28/2002	WO2002035235A3 Net as regulator of angiogenic expression
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2001098360A3 Gp354 nucleic acids and polypeptides
11/28/2002	WO2001095919A3 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
11/28/2002	WO2001090401A3 Yeast strains to identify specific inhibitors of polo kinases
11/28/2002	WO2001089542A3 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/28/2002	WO2001087227A3 Drug containing polymeric micelles
11/28/2002	WO2001082897A3 Liposome drug delivery
11/28/2002	WO2001081415A3 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/28/2002	WO2001074993A3 A novel polypeptide - human zinc finger protein 17 and the polynucleotide encoding said polypeptide
11/28/2002	WO2001068911A3 Diagnosis of diseases associated with the cell cycle
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	US20020178456 Polyclonal antibodies for use inthe treatment and prevention of bacteria, fungi, virus and parasites infections
11/28/2002	US20020177706 Rheumatic diseases; antiarthritic agents; antitumor agents
11/28/2002	US20020177618 ERK (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
11/28/2002	US20020177615 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
11/28/2002	US20020177609 Fatty alcohol drug conjugates
11/28/2002	US20020177601 Inhibit the signal transduction by tyrosine kinases; e.g. 4-(3-chloro-4-fluorophenylamino)-6-(3-(4-(methoxycarbonyl-methyl)-1 -piperazinyl)propyloxy)-7-methoxyquinazoline; use such as antitumor agent
11/28/2002	US20020177565 Toso proteins and related molecules which have an inhibitory effect on TNF mediated apoptosis
11/28/2002	US20020177561 With an average degree of polymerisation of at least 15
11/28/2002	US20020177552 Colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions; alternatively, antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a
11/28/2002	US20020177550 Administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE).
11/28/2002	US20020177548 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
11/28/2002	US20020177545 Compositions and methods for treating gonadotrophin related illnesses
11/28/2002	US20020177213 Tissue plasminogen activator-like protease
11/28/2002	US20020177145 Detection and classification of nervous system progenitor cells; obtain tissue, monitor expression of daedalos protein in sample, compare to control, ampified daedalos expression indicates presence of nervous system progenitor cells
11/28/2002	US20020176897 Treating cancer cells that express a membrane protein tNOX, a hormone-insensitive and drug-responsive form of NOX (NADH oxidase) specific to cancer cells
11/28/2002	US20020176860 A polypeptide providing cytotoxicity, being fused to an apoptin rendering the fusion protein functionally available in aberrant cells and not functionally available in non-aberrant cells
11/28/2002	US20020176852 Mitogenic oxygenase regulators
11/28/2002	US20020176850 Immunotherapy of cancer with allogeneic lymphocytes
11/28/2002	US20020176849 Endomural therapy
11/28/2002	US20020176847 Administering to a mammal viral vectors for treating and preventing atherosclerosis, osteoporosis, cardiovascular disease, Alzheimer's disease, diabetes mellitus, infectious diseases, cancer, and inherited disorders
11/28/2002	US20020176819 Gastrin receptor-avid peptide conjugates
11/28/2002	US20020176818 Radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid
11/28/2002	DE10125763A1 New use of indirubin derivatives as VEGF inhibitors useful for preparing medicaments useful for e.g. treating cancer, autoimmune diseases, cardiovascular diseases or viral infections
11/28/2002	DE10123586A1 New 3,5-diamino-1,2,4-triazole derivatives, are cyclin dependent kinase inhibitors useful for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
11/28/2002	DE10123505A1 New immunoconjugate comprising egg yolk immunoglobulin Y, useful for treating e.g. inflammation or infection, is derived from specific pathogen-free hens
11/28/2002	CA2489768A1 Methods for preparation and use of psorospermin analogs
11/28/2002	CA2449442A1 Combination medicament for treatment of neoplastic diseases
11/28/2002	CA2448253A1 Human cdnas and proteins and uses thereof
11/28/2002	CA2448197A1 Tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	CA2448191A1 Tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	CA2448186A1 Novel smg-1
11/28/2002	CA2448076A1 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
11/28/2002	CA2448018A1 Compositions and methods for inhibiting metastasis
11/28/2002	CA2447940A1 Urazole compounds useful as anti-inflammatory agents
11/28/2002	CA2447598A1 Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
11/28/2002	CA2447340A1 Kinases and phosphatases
11/28/2002	CA2447338A1 Receptors and membrane-associated proteins
11/28/2002	CA2447313A1 Monoclonal antibody neutralising cathepsin b activity and uses thereof
11/28/2002	CA2447231A1 Methods for inhibiting angiogenesis
11/28/2002	CA2447161A1 Conjugates and compositions for cellular delivery
11/28/2002	CA2447103A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002	CA2447066A1 Method of treatment for cancers associated with elevated
11/28/2002	CA2447023A1 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	CA2447020A1 The use of 4-aminopyridine derivatives for the treatment of mglur5 receptor mediated diseases
11/28/2002	CA2446734A1 Antibodies against tumor necrosis factor delta (april)
11/28/2002	CA2446510A1 Therapeutic agent for tumor of neural origin
11/28/2002	CA2446155A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
11/28/2002	CA2445631A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	CA2444787A1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
11/28/2002	CA2443438A1 Cytotoxic cd44 antibody immunoconjugates
11/28/2002	CA2443437A1 Antibodies specific for cd44v6
11/28/2002	CA2443342A1 Mage-a3 peptides presented by hla class ii molecules
11/28/2002	CA2441801A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/28/2002	CA2427619A1 Pharmaceutically active isoindoline derivatives
11/27/2002	EP1260512A1 Novel cyclic amide derivatives
11/27/2002	EP1260223A1 Taxanes having furyl or thienyl substituted side-chain
11/27/2002	EP1260222A1 Butenyl-substituted taxanes and composition
11/27/2002	EP1259813A2 Diagnosis and treatment of malignant neoplasms
11/27/2002	EP1259812A2 Breast, gastric and prostate cancer associated antigens and uses therefor
11/27/2002	EP1259647A2 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
11/27/2002	EP1259638A2 Methods for selectively modulating survivin apoptosis pathways
11/27/2002	EP1259626A2 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins and screening methods for modulators
11/27/2002	EP1259621A2 Lipid metabolism enzymes

1 ... 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 ... 2211